Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allena Pharmaceuticals, Inc.ALNA · Entity 130904 | Director · 10% owner | June 05, 2019 | June 07, 2019 |
| Blueprint Medicines CorpBPMC · Entity 77326 | 10% owner | February 27, 2017 | February 28, 2017 |
| CONSTELLATION PHARMACEUTICALS INCCNST · Entity 137050 | Director · 10% owner | June 06, 2019 | June 10, 2019 |
| Decibel Therapeutics, Inc.[DBTX] · Entity 109458 | 10% owner | February 11, 2021 | February 12, 2021 |
| Jounce Therapeutics, Inc.JNCE · Entity 15754 | 10% owner | November 12, 2021 | November 16, 2021 |
| KALA BIO, Inc.KALA · Entity 7964 | Director | July 25, 2017 | July 26, 2017 |
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | 10% owner | May 06, 2021 | May 10, 2021 |
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | 10% owner | August 30, 2018 | September 04, 2018 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | 10% owner | January 12, 2021 | January 14, 2021 |
| Revolution Medicines, Inc.RVMD · Entity 606 | 10% owner | June 08, 2022 | June 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allena Pharmaceuticals, Inc.
Report date June 05, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.59 · Expires 2029-06-04 | Direct | 14,000 |
Reported balance
After 2019-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-05 · Grant · Acquired 14,000 · Balance 14,000 F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders.
Blueprint Medicines Corp
Report date February 27, 2017 · Filed February 28, 2017
Jointly reported with Third Rock Ventures II, L.P., Third Rock Ventures GP II, L.P., TRV GP II, LLC, Levin Mark J, STARR KEVIN P
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,453,753 |
Reported balance
After 2017-02-27 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2017-02-27 · Other · Disposed 1,000,000 · Balance 3,453,753 F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed on February 27, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 141,240 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 141,240 F3: These shares are directly held by Tepper. |
| Common StockSEC Table I · non-derivative | Direct | 141,244 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 141,244 F4: These shares are directly held by Levin. |
| Common StockSEC Table I · non-derivative | Direct | 34,750 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 34,750 F5: These shares are directly held by Starr. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed on February 27, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: These shares are directly held by Tepper.
F4: These shares are directly held by Levin.
F5: These shares are directly held by Starr.
CONSTELLATION PHARMACEUTICALS INC
Report date June 06, 2019 · Filed June 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12 · Expires 2029-06-05 | Direct | 13,171 |
Reported balance
After 2019-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-06 · Grant · Acquired 13,171 · Balance 13,171 F1: This option was granted on June 6, 2019 and will vest as to all shares underlying the option on June 6, 2020, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 6, 2019 and will vest as to all shares underlying the option on June 6, 2020, subject to continued service.
Decibel Therapeutics, Inc.
Report date February 11, 2021 · Filed February 12, 2021
Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC, Levin Mark J, STARR KEVIN P
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,169 |
Reported balance
Holding disclosure · report date 2021-02-11 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 47,169 F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-11 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The Series A Preferred Stock is convertible into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date. F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The Series C Preferred Stock is convertible into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-11 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: The Series D Preferred Stock is convertible into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date. F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F2: The Series A Preferred Stock is convertible into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
F3: The Series C Preferred Stock is convertible into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date
F4: The Series D Preferred Stock is convertible into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
Jounce Therapeutics, Inc.
Report date November 12, 2021 · Filed November 16, 2021
Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC, STARR KEVIN P, Levin Mark J
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,148,780 |
Reported balance
After 2021-11-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-11-12 · Sale · Disposed 1,900,000 · Balance 1,148,780 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $8.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,697,829 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,697,829 F3: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 284,344 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 284,344 F4: The shares are directly held by Levin. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 283,850 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 283,850 F5: The shares are directly held by Starr. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 283,858 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 283,858 F6: The shares are directly held by Tepper. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $8.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F4: The shares are directly held by Levin.
F5: The shares are directly held by Starr.
F6: The shares are directly held by Tepper.
KALA BIO, Inc.
Report date July 25, 2017 · Filed July 26, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote. | 1,621,092 |
Reported balance
After 2017-07-25 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-07-25 · Conversion · Acquired 1,621,092 · Balance 1,621,092 F1: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4: These shares are held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Levin, Starr and Tepper. Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Series Seed Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote. | 0 |
Reported balance
After 2017-07-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-07-25 · Conversion · Disposed 3,677,374 · Balance 0 F1: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote. | 0 |
Reported balance
After 2017-07-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-07-25 · Conversion · Disposed 2,500,000 · Balance 0 F1: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote. | 0 |
Reported balance
After 2017-07-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-07-25 · Conversion · Disposed 2,265,764 · Balance 0 F1: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Series B Preferred Stock Warrant (right to buy)SEC Table II · derivative / convertible security | IndirectSee footnote. | 0 |
Reported balance
After 2017-07-25 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-07-25 · Conversion · Disposed 173,611 · Balance 0 F2: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021. F3: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common Stock Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.50 | IndirectSee footnote. | 33,333 |
Reported balance
After 2017-07-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-07-25 · Conversion · Acquired 33,333 · Balance 33,333 F2: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021. F4: These shares are held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Levin, Starr and Tepper. Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: The Series B Preferred Stock Warrant was exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrant automatically became exercisable for 33,333 shares of Common Stock at an exercise price of $7.50 per share. The Warrant is exercisable at any time at the holder's election on or before April 16, 2021.
F3: These shares were held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F4: These shares are held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Levin, Starr and Tepper. Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
Nurix Therapeutics, Inc.
Report date May 06, 2021 · Filed May 10, 2021
Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC, STARR KEVIN P, Levin Mark J
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,422,549 |
Reported balance
After 2021-05-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-05-06 · Other · Disposed 1,085,784 · Balance 3,422,549 F1: Pursuant to a 10b5-1 trading plan adopted on October 29, 2020 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,085,784 shares of Common Stock of the Issuer (the "Shares") on May 6, 2021 to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 78,118 |
Reported balance
Holding disclosure · report date 2021-05-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 78,118 F3: The shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 8,677 |
Reported balance
Holding disclosure · report date 2021-05-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 8,677 F4: The shares are directly held by Levin Family 2014 Irrevocable Trust. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 86,798 |
Reported balance
Holding disclosure · report date 2021-05-06 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 86,798 F5: The shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 86,799 |
Reported balance
Holding disclosure · report date 2021-05-06 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 86,799 F6: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a 10b5-1 trading plan adopted on October 29, 2020 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,085,784 shares of Common Stock of the Issuer (the "Shares") on May 6, 2021 to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: The shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.
F4: The shares are directly held by Levin Family 2014 Irrevocable Trust. Includes Shares received in the distributions described in footnote (1) above.
F5: The shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.
F6: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.
RHYTHM PHARMACEUTICALS, INC.
Report date August 30, 2018 · Filed September 04, 2018
Jointly reported with THIRD ROCK VENTURES LP, Third Rock Ventures GP, L.P., TRV GP, LLC, STARR KEVIN P, Levin Mark J
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,981,437 |
Reported balance
After 2018-08-30 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2018-08-30 · Other · Disposed 1,000,000 · Balance 2,981,437 F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), Third Rock Ventures GP, L.P. ("TRV GP") and TRV GP, LLC ("TRV GP LLC"), TRV distributed on August 30, 2018, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP, the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 99,105 |
Reported balance
Holding disclosure · report date 2018-08-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 99,105 F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | Direct | 99,105 |
Reported balance
Holding disclosure · report date 2018-08-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 99,105 F4: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | Direct | 99,105 |
Reported balance
Holding disclosure · report date 2018-08-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 99,105 F5: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), Third Rock Ventures GP, L.P. ("TRV GP") and TRV GP, LLC ("TRV GP LLC"), TRV distributed on August 30, 2018, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP, the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.
F4: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.
F5: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.
Relay Therapeutics, Inc.
Report date January 12, 2021 · Filed January 14, 2021
Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC, STARR KEVIN P, Levin Mark J, Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., TRV GP IV, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,739,918 |
Last balance in matching sequence
After 2021-01-13 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2021-01-12 · Sale · Disposed 1,500,000 · Balance 9,051,115 F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Row 2 · 2021-01-13 · Sale · Disposed 1,247,873 · Balance 7,803,242 F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Row 3 · 2021-01-13 · Sale · Disposed 8,727 · Balance 7,794,515 F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Row 4 · 2021-01-13 · Sale · Disposed 42,860 · Balance 7,751,655 F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4). F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Row 5 · 2021-01-13 · Sale · Disposed 4,325 · Balance 7,747,330 F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5). F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Row 6 · 2021-01-13 · Sale · Disposed 7,412 · Balance 7,739,918 F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6). F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Last balance in matching sequence
After 2021-01-14 transaction · row 12
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 7 · 2021-01-13 · Sale · Disposed 805,050 · Balance 2,006,147 F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7). F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Row 8 · 2021-01-13 · Sale · Disposed 5,630 · Balance 2,000,517 F8: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8). F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Row 9 · 2021-01-13 · Sale · Disposed 27,650 · Balance 1,972,867 F9: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9). F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Row 10 · 2021-01-13 · Sale · Disposed 2,791 · Balance 1,970,076 F10: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10). F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Row 11 · 2021-01-13 · Sale · Disposed 4,782 · Balance 1,965,294 F11: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11). F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Row 12 · 2021-01-14 · Sale · Disposed 1,965,294 · Balance 0 F12: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12). F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).
F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).
F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5).
F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).
F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7).
F8: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8).
F9: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9).
F10: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10).
F11: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11).
F12: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12).
F13: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F14: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.
Revolution Medicines, Inc.
Report date June 08, 2022 · Filed June 10, 2022
Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,104,130 |
Reported balance
After 2022-06-08 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2022-06-08 · Sale · Disposed 419,901 · Balance 5,104,130 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares |
| Common StockSEC Table I · non-derivative | Direct | 129,258 |
Reported balance
Holding disclosure · report date 2022-06-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 129,258 F4: The shares are directly held by Tepper. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
Holding disclosure · report date 2022-06-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 0 F3: Third Rock Ventures IV, L.P. ("TRV IV") directly holds 1,419,900 shares of Common Stock of the Issuer. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons and TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
F2: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares
F3: Third Rock Ventures IV, L.P. ("TRV IV") directly holds 1,419,900 shares of Common Stock of the Issuer. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons and TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
F4: The shares are directly held by Tepper.
Past disclosures · reporting ended (7)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CytomX Therapeutics, Inc.
Report date October 18, 2017 · Filed October 19, 2017
Jointly reported with THIRD ROCK VENTURES LP, Third Rock Ventures GP, L.P., TRV GP, LLC, Levin Mark J, STARR KEVIN P
Section 16 reporting ended · disclosed 2017-10-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,320,348 |
Reported balance
After 2017-10-18 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2017-10-18 · Other · Disposed 1,000,000 · Balance 3,320,348 F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on October 18, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 116,927 |
Reported balance
Holding disclosure · report date 2017-10-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 116,927 F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | Direct | 145,286 |
Reported balance
Holding disclosure · report date 2017-10-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 145,286 F4: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | Direct | 85,509 |
Reported balance
Holding disclosure · report date 2017-10-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 85,509 F5: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on October 18, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.
F4: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.
F5: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.
Fulcrum Therapeutics, Inc.
Report date December 13, 2022 · Filed December 15, 2022
Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC
Section 16 reporting ended · disclosed 2022-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,962,202 |
Reported balance
After 2022-12-13 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2022-12-13 · Other · Disposed 2,000,000 · Balance 1,962,202 F1: On December 13, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 156,189 |
Reported balance
Holding disclosure · report date 2022-12-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 156,189 F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,343,154 |
Reported balance
Holding disclosure · report date 2022-12-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,343,154 F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 13, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.
F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.
Global Blood Therapeutics, Inc.
Report date June 14, 2017 · Filed June 16, 2017
Jointly reported with Third Rock Ventures II, L.P., Third Rock Ventures GP II, L.P., TRV GP II, LLC, Levin Mark J, STARR KEVIN P
Section 16 reporting ended · disclosed 2017-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,475,191 |
Reported balance
After 2017-06-14 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2017-06-14 · Other · Disposed 1,000,000 · Balance 2,475,191 F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on June 14, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 212,204 |
Reported balance
Holding disclosure · report date 2017-06-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 212,204 F3: These shares are directly held by Levin. Includes shares received in the distributions described in footnote (1) above. F4: In addition to the reported shares, Third Rock Ventures III, L.P. ("TRV III") directly holds 285,713 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 200,249 |
Reported balance
Holding disclosure · report date 2017-06-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 200,249 F5: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above. F4: In addition to the reported shares, Third Rock Ventures III, L.P. ("TRV III") directly holds 285,713 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 277,980 |
Reported balance
Holding disclosure · report date 2017-06-14 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 277,980 F6: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above. F4: In addition to the reported shares, Third Rock Ventures III, L.P. ("TRV III") directly holds 285,713 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on June 14, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: These shares are directly held by Levin. Includes shares received in the distributions described in footnote (1) above.
F4: In addition to the reported shares, Third Rock Ventures III, L.P. ("TRV III") directly holds 285,713 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F5: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.
F6: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.
MyoKardia, Inc.
Report date March 07, 2018 · Filed March 07, 2018
Jointly reported with Third Rock Ventures II, L.P., Third Rock Ventures GP II, L.P., TRV GP II, LLC, Levin Mark J
Section 16 reporting ended · disclosed 2018-03-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 885,104 |
Reported balance
After 2018-03-07 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2018-03-07 · Other · Disposed 2,000,000 · Balance 885,104 F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on March 7, 2018, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 265,057 |
Reported balance
Holding disclosure · report date 2018-03-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 265,057 F3: Third Rock Ventures III, L.P. ("TRV III") directly holds 680,272 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F4: The shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | Direct | 280,057 |
Reported balance
Holding disclosure · report date 2018-03-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 280,057 F3: Third Rock Ventures III, L.P. ("TRV III") directly holds 680,272 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F5: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on March 7, 2018, for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II LLC. The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: Third Rock Ventures III, L.P. ("TRV III") directly holds 680,272 shares of Common Stock of the Issuer. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Levin, Starr and Tepper. Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F4: The shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.
F5: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.
Neon Therapeutics, Inc.
Report date May 06, 2020 · Filed May 06, 2020
Section 16 reporting ended · disclosed 2020-05-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-05-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-05-06 · Disposition to issuer · Disposed 9,741,636 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. F2: These Shares were directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the Shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-06 · Disposition to issuer · Disposed 14,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-06 · Disposition to issuer · Disposed 18,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted.
F2: These Shares were directly held by TRV III. The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the Shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such Shares.
F3: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").
PLIANT THERAPEUTICS, INC.
Report date November 29, 2022 · Filed December 01, 2022
Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC
Section 16 reporting ended · disclosed 2022-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,839,160 |
Reported balance
After 2022-11-29 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2022-11-29 · Other · Disposed 2,000,000 · Balance 1,839,160 F1: On November 29, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 229,504 |
Reported balance
Holding disclosure · report date 2022-11-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 229,504 F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,132,867 |
Reported balance
Holding disclosure · report date 2022-11-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,132,867 F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 29, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.
F4: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.
Voyager Therapeutics, Inc.
Report date February 02, 2023 · Filed February 06, 2023
Jointly reported with Third Rock Ventures III, L.P., Third Rock Ventures GP III, L.P., TRV GP III, LLC
Section 16 reporting ended · disclosed 2023-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,185,291 |
Reported balance
After 2023-02-02 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2023-02-02 · Other · Disposed 1,500,000 · Balance 3,185,291 F1: On February 2, 2023, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 86,265 |
Reported balance
Holding disclosure · report date 2023-02-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 86,265 F3: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 2, 2023, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: The shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2023 Filed Feb 6, 2023 21:30 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | OtherCommon Stock | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-004046 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,185,291 F1 · kind: On February 2, 2023, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On February 2, 2023, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 00:26 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 128,642 | $9.32 | $1,198,943.44 |
DisclosureSEC source: 0000899243-23-003161 · doc4.xml · nonDerivative · entry 3 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,685,291 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 00:26 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 185,000 | $9.25 | $1,711,250.00 |
DisclosureSEC source: 0000899243-23-003161 · doc4.xml · nonDerivative · entry 2 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,813,933 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.15 to $9.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| January 30, 2023 Filed Feb 2, 2023 00:26 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 75,000 | $9.03 | $677,250.00 |
DisclosureSEC source: 0000899243-23-003161 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,998,933 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:30 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 50,000 | $9.02 | $451,000.00 |
DisclosureSEC source: 0000899243-23-003044 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,073,933 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 22:23 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 50,000 | $9.22 | $461,000.00 |
DisclosureSEC source: 0000899243-23-002770 · doc4.xml · nonDerivative · entry 2 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,123,933 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 22:23 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 100,000 | $9.27 | $927,000.00 |
DisclosureSEC source: 0000899243-23-002770 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,173,933 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 23:20 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 55,000 | $9.06 | $498,300.00 |
DisclosureSEC source: 0000899243-23-002483 · doc4.xml · nonDerivative · entry 2 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,273,933 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 23:20 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 100,000 | $9.15 | $915,000.00 |
DisclosureSEC source: 0000899243-23-002483 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,328,933 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 16:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | OtherCommon Stock | 2,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-038602 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,962,202 F1 · kind: On December 13, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On December 13, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 16:47 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | OtherCommon Stock | 2,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-037288 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,839,160 F1 · kind: On November 29, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On November 29, 2022, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 16:59 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | OtherCommon Stock | 2,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-031705 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,839,160 F1 · kind: Pursuant to a 10b5-1 trading plan adopted on August 5, 2022 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") on September 20, 2022, to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a 10b5-1 trading plan adopted on August 5, 2022 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 2,000,000 shares of Common Stock of the Issuer (the "Shares") on September 20, 2022, to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 20:15 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 200,000 | $6.22 | $1,244,000.00 |
DisclosureSEC source: 0000899243-22-029856 · doc4.xml · nonDerivative · entry 2 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,428,933 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.15 to $6.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:15 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 149,972 | $6.09 | $913,329.48 |
DisclosureSEC source: 0000899243-22-029856 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,628,933 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 20:15 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 128,456 | $6.04 | $775,874.24 |
DisclosureSEC source: 0000899243-22-029151 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,778,905 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 20:22 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 135,808 | $6.04 | $820,280.32 |
DisclosureSEC source: 0000899243-22-028793 · doc4.xml · nonDerivative · entry 2 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,907,361 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 20:22 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 348,007 | $6.12 | $2,129,802.84 |
DisclosureSEC source: 0000899243-22-028793 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,043,169 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.376, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 19:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 419,901 | $20.25 | $8,502,995.25 |
DisclosureSEC source: 0000899243-22-022013 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,104,130 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $20.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:57 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 1,900,000 | $8.38 | $15,922,000.00 |
DisclosureSEC source: 0000899243-21-044916 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,780 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $8.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 17:26 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | OtherCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-044424 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,962,202 F1 · kind: Pursuant to a 10b5-1 trading plan adopted on September 8, 2021 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") on November 10, 2021, to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a 10b5-1 trading plan adopted on September 8, 2021 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") on November 10, 2021, to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 16:13 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | OtherCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-037614 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,962,202 F1 · kind: Pursuant to a 10b5-1 trading plan adopted on March 30, 2021 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") on September 22, 2021, to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a 10b5-1 trading plan adopted on March 30, 2021 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") on September 22, 2021, to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 16:15 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | OtherCommon Stock | 1,750,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036411 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,697,829 F1 · kind: Pursuant to a 10b5-1 trading plan adopted on November 18, 2020 by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed for no consideration, 1,750,000 shares of Common Stock of the Issuer (the "Shares") on September 15, 2021, to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a 10b5-1 trading plan adopted on November 18, 2020 by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed for no consideration, 1,750,000 shares of Common Stock of the Issuer (the "Shares") on September 15, 2021, to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 16:19 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | OtherCommon Stock | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-023555 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,447,829 F1 · kind: Pursuant to a 10b5-1 trading plan adopted on November 18, 2020 by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") on June 10, 2021, to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a 10b5-1 trading plan adopted on November 18, 2020 by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") on June 10, 2021, to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 18:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 164,996 | $30.23 | $4,987,829.08 |
DisclosureSEC source: 0000899243-21-022345 · doc4.xml · nonDerivative · entry 2 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). F2 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 18:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 378,117 | $30.20 | $11,419,133.40 |
DisclosureSEC source: 0000899243-21-022345 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,996 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| May 26, 2021 Filed May 27, 2021 17:43 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,231,204 | $30.53 | $37,588,658.12 |
DisclosureSEC source: 0000899243-21-020885 · doc4.xml · nonDerivative · entry 2 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,113 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). F2 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| May 25, 2021 Filed May 27, 2021 17:43 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 135,000 | $30.93 | $4,175,550.00 |
DisclosureSEC source: 0000899243-21-020885 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,774,317 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.85 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| May 25, 2021 Filed May 27, 2021 17:42 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 552,520 | $8.00 | $4,420,160.00 |
DisclosureSEC source: 0000899243-21-020883 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,947,829 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| May 06, 2021 Filed May 10, 2021 16:41 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | OtherCommon Stock | 1,085,784 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018932 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,422,549 F1 · kind: Pursuant to a 10b5-1 trading plan adopted on October 29, 2020 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,085,784 shares of Common Stock of the Issuer (the "Shares") on May 6, 2021 to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a 10b5-1 trading plan adopted on October 29, 2020 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,085,784 shares of Common Stock of the Issuer (the "Shares") on May 6, 2021 to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:15 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | OtherCommon Stock | 1,250,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-011577 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500,349 F1 · kind: Pursuant to a 10b5-1 trading plan adopted on November 18, 2020 by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed for no consideration, 1,250,000 shares of Common Stock of the Issuer (the "Shares") on March 11, 2021, to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a 10b5-1 trading plan adopted on November 18, 2020 by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed for no consideration, 1,250,000 shares of Common Stock of the Issuer (the "Shares") on March 11, 2021, to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:00 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 1,450,000 | $11.75 | $17,037,500.00 |
DisclosureSEC source: 0000899243-21-009481 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,750,349 F1 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 18:12 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | OtherCommon Stock | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-008465 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,524,031 F1 · kind: On February 24, 2021, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP II"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On February 24, 2021, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP II"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 16:11 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | OtherCommon Stock | 914,216 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-005161 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,508,333 F1 · kind: On February 4, 2021, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 914,216 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On February 4, 2021, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 914,216 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| January 14, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,965,294 | $41.00 | $80,577,054.00 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 12 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F12 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12). F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 4,782 | $44.73 | $213,898.86 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 11 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,965,294 F11 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (11). F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,791 | $44.00 | $122,804.00 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 10 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,970,076 F10 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10). F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 27,650 | $42.12 | $1,164,618.00 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 9 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,972,867 F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9). F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 5,630 | $41.08 | $231,280.40 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 8 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,000,517 F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8). F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 805,050 | $40.01 | $32,210,050.50 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 7 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,006,147 F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7). F13 · ownership.nature: These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of the reporting persons, except for TRV IV, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.nature: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 7,412 | $44.73 | $331,538.76 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 6 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,739,918 F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6). F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 4,325 | $44.00 | $190,300.00 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 5 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,747,330 F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.04 to $44.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5). F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 42,860 | $42.12 | $1,805,263.20 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 4 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,751,655 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4). F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 8,727 | $41.08 | $358,505.16 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 3 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,794,515 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,247,873 | $40.01 | $49,927,398.73 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 2 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,803,242 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 20:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,500,000 | $40.00 | $60,000,000.00 |
DisclosureSEC source: 0000899243-21-002117 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Third Rock Ventures IV, L.P. · CIK 0001688327 · 10% owner Third Rock Ventures GP IV, L.P. · CIK 0001688326 · 10% owner TRV GP IV, LLC · CIK 0001688325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,051,115 F1 · ownership.direct: These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. F14 · ownership.direct: Each of the reporting persons disclaims the existence of a Section 13(d) "group" as between the TRV III related parties and the TRV IV related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 18:45 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | OtherCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-032784 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,024,031 F1 · kind: On December 2, 2020, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On December 2, 2020, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 16:42 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 15,000 | $7.01 | $105,075.00 |
DisclosureSEC source: 0000899243-20-031919 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200,349 F1 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 17:42 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 15,000 | $7.25 | $108,772.50 |
DisclosureSEC source: 0000899243-20-031680 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,215,349 F1 · ownership.direct: These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 20:26 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | OtherCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031066 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures II, L.P. · CIK 0001488495 · 10% owner Third Rock Ventures GP II, L.P. · CIK 0001614061 · 10% owner TRV GP II, LLC · CIK 0001614073 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,230,349 F1 · kind: On November 11, 2020, Third Rock Ventures II, L.P. ("TRV II") distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On November 11, 2020, Third Rock Ventures II, L.P. ("TRV II") distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV II. The general partner of TRV II is TRV GP II. The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 16:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | OtherCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-024900 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,024,031 F1 · kind: On September 9, 2020, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On September 9, 2020, Third Rock Ventures III, L.P. ("TRV III") distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.